It is well known that the amplitude of mismatch negativity (MMN), a component of event-related potentials, is attenuated in chronic schizophrenia. Although the neural basis of the MMN deficits is not fully understood, there is growing evidence that MMN amplitudes are attenuated even in the early stages of schizophrenia and that the association with cognitive function and functional outcomes and the prognostic properties vary by the stimulus condition. Because MMN is a translatable biomarker that can be measured in non-human animals, MMN studies in the early stages of schizophrenia may help to elucidate the pathophysiology of the disease and provide effective early support for patients with schizophrenia. We therefore reviewed MMN studies of the early stages of schizophrenia, such as ultra-high risk for psychosis (UHR) and first episode psychosis/schizophrenia (FEP/FES), from the perspective of progressive changes in MMN, associations with cognitive function and functional outcomes, pathophysiology, and prognosis prediction of UHR, as well as focusing on differences in stimulus conditions.
View full abstract